Project description
Novel venous leg ulcer treatment
Chronic venous disease is associated with poor blood circulation and blood pooling in the legs. In nearly half of the adult population over 60 years of age, this leads to venous leg ulcers at some point in their life. Treatment costs healthcare systems billions of euros every year, but the recurrence rate is high, necessitating effective alternatives. Funded by the European Innovation Council, the EnVena project is introducing a novel medical device that mimics the body’s natural healing response. The device provides an effective minimally invasive treatment against both varicose veins and venous ulcers but without harmful side effects.
Objective
Chronic venous disease is one of the most common diseases in the developed world, affecting up to 60% of adults over the age of 50. Chronic venous disease is the leading cause of Venous Leg Ulcers which are chronic open sores, usually on the inside of the leg that will not heal without specialist treatment.
The total costs associated with managing venous disease patients across Europe and the US is €33.4 billion per year, representing 2.5% of total healthcare expenditure.
Most patients are treated with ineffective compression bandaging which does not treat the underlying cause and has an unacceptably high recurrence rate. These bandages are also sent to landfill with a high environmental impact
EnVena is the world’s first device to mimic the body’s natural healing response to deliver an effective treatment to venous leg ulcer patients.
Fields of science
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-AG - HORIZON Action Grant Budget-BasedCoordinator
H91 DCH9 GALWAY
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.